MARY MILLER: Open Payments
NPI 1033721477 · ANNISTON, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$463 in 22 payments from 8 companies in 2025. Trend: 2023 $272 · 2024 $348 · 2025 $463
Food & beverage: $463
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $113 |
| AstraZeneca Pharmaceuticals LP | 5 | $97 |
| Neurocrine BioSciences, Inc. | 3 | $86 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $70 |
| Indivior Inc. | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Verona Pharma, Inc. | 1 | $16 |
Products named: CAPLYTA, INGREZZA, Kerendia, BREZTRI, SUBLOCADE, AIRSUPRA, REXULTI, AUSTEDO XR.
Industry payments across AL — which companies pay providers there.
